Brazil's Health Ministry to propose injectable HIV prevention drug for public system
Brazil's Ministry of Health intends to submit a proposal to the National Commission for the Incorporation of Technologies in the Unified Health System (Conitec) next week to include cabotegravir in the public healthcare system (SUS). Cabotegravir is an injectable medication used for HIV prevention. The announcement was made by Health Minister Alexandre Padilha on Monday, May 27th, during the International AIDS Conference in Rio de Janeiro. Minister Padilha stated that the pharmaceutical company producing the drug has presented an acceptable price to the Brazilian government, though the negotiated amount was not disclosed. The submission of the proposal does not guarantee immediate availability; Conitec will first evaluate scientific evidence, costs, and the potential impact of incorporating cabotegravir. Unlike the current oral PrEP available through SUS, which requires daily pill intake, cabotegravir is administered via an injection every two months. This injectable form was approved by Brazil's National Health Surveillance Agency (Anvisa) in 2023 and by the U.S. Food and Drug Administration (FDA) in 2021. The World Health Organization (WHO) recommended cabotegravir for HIV prevention in 2022. Current HIV prevention in Brazil relies on oral PrEP, a combination of two daily medications (tenofovir/emtricitabine), provided free by SUS. Cabotegravir offers a long-acting alternative, with initial doses given four weeks apart, followed by injections every eight weeks. Clinical trials, including those conducted in Brazil, demonstrated cabotegravir to be safe and highly effective, showing a 69% greater efficacy compared to daily oral pills, particularly benefiting adherence and convenience.
The Brazilian Ministry of Health's move to consider an injectable HIV prevention drug signals a proactive approach to public health, aiming to improve treatment adherence and efficacy. By potentially integrating cabotegravir into the SUS, the government addresses the limitations of daily oral regimens, which can suffer from compliance issues. This decision reflects a global trend toward more convenient and effective biomedical HIV prevention strategies. The evaluation process by Conitec will be crucial in balancing innovation with fiscal responsibility, ensuring that new technologies are both clinically beneficial and economically sustainable within the public health framework. As AI continues to advance diagnostics and personalized medicine, such public health initiatives will need to adapt to evolving technological landscapes and ensure equitable access to cutting-edge preventative care.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.